Table 1.
Characteristics of included studies
Study | Country | The original disease | Sample (N) |
Sex (F/M) |
Age (yr) |
Treatment |
Duration of study | Follow-up period | Measurement | Outcome | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intervention | Control | Intervention | Control | Intervention | Control | Intervention | Control | |||||||
Zang et al. 2014 [33] | China | PTSD | 10 | 10 | 9/1 | 8/2 | 53.5±1.24 | 56.6±1.47 | NET 4 sessions frequency: weekly or biweekly | WLC received the NET-R treatment after a three week waiting period | 3 weeks | 3 months | HADS | * † ‡ § |
MSPSS | ||||||||||||||
CIQQ-S | ||||||||||||||
Zang et al. 2013 [34] | China | PTSD | 11 | 11 | 8/3 | 9/2 | 56.64±12.22 | 54.82±11.59 | NET 4 therapy sessions of 60–90 min each, which lasted 2 weeks | WLC after a waiting period (2 weeks) | 2 weeks | 2 months | HADS | * † ‡ § |
MSPSS | ||||||||||||||
CIQQ-S | ||||||||||||||
Ertl et al. 2011 [41] | Northern Uganda | PTSD | 29 | 28 | 16/13 | 19/9 | 18.66±3.77 | 18.32±4.30 | NET 8 individual sessions lasted between 90 and 120 min and were scheduled 3 times a week | WLC | - | 3, 6, 12 months | CAPS | † ǁ ¶ |
MINI | ||||||||||||||
PSQ | ||||||||||||||
Rocha et al. 2018 [37] | American | TOP | 26 | 67 | 26/0 | 67/0 | 32.3±5.97 | 33.3±6.66 | Cognitive narrative intervention: the manual has four weekly sessions of 60 min each | Usual care | 4 weeks | 2 months | BDI | * † |
Zung | ||||||||||||||
Vega et al. 2011 [36] | Spain | Oncologic disease | 39 | 33 | 34/15 | 24/9 | 53.2±9.5 | 56±10.8 | NT plus escitalopram: the therapy was carried out individually during 12–45 min weekly sessions | Escitalopram plus usual care: escitalopram (10–20 mg QD) plus usual care | - | 6 months | HADS-D | † |
Alghamdi et al. 2015 [40] | Saudi Arabia | PTSD | 17 | 17 | 0/17 | 0/17 | 28.7±4.1 | 32.2±6.23 | NET 4 therapy sessions of 60–90 min each, which lasted 3 weeks | WLC after 3 weeks waiting period | 3 weeks | 3 weeks | HADS | * † |
Li et al. 2018 [43] | China | Kidney cancer | 60 | 60 | 31/29 | 25/35 | 54.67±2.1 | 52.67±3.8 | Narrative nursing+usual care: continuous intervention for 4 weeks, once a week, about 45–60 min each time, telephone visit once a week | Usual care: diagnosis | 4 weeks | 4 weeks | PHQ-9 | * † |
- evaluation | GAD-7 | |||||||||||||
- personalized psychological stem | ||||||||||||||
- telephone follow | ||||||||||||||
- up | ||||||||||||||
Salloum et al. 2012 [35] | US | PTSD | 37 | 32 | 19/18 | 12/21 | 9.6±1.52 | 10.7±1.52 | Narrative restorative totol 10 sessions, every session approximately 45 min | Usual care | - | Post, 3, 12 month | MFQ-C | † ‡ |
MSPSS | ||||||||||||||
Wise et al. 2018 [39] | US | Advanced cancer | 49 | 37 | 40/9 | 28/9 | 57±8.5 | 57±9.1 | Narritive interview miLivingStory, the treatment condition, three components | Usual care miOwnResources, the ‘‘control’’ website, contained the miLivingStory cancer information, and support, but no story tips | 2, 4 months | POMS-SF | * † | |
Lloyd-Williams et al. 2018 [38] | England | Moderate to severe depression | 33 | 24 | 33/9 | 17/7 | 66.2 | 63.4 | Narrative intervention in addition to usual care lasting from 25 to 60 min | Usual care | 2, 4, 6 weeks | PHQ-9 | † | |
Zong et al. 2017 [42] | China | Advanced lung cancer | 62 | 62 | 25/37 | 26/36 | 55.29±12.03 | 57.82±10.96 | Narration medicine | Routine perioperative Care | SAS | * † | ||
SDS |
anxiety;
depression;
social support;
negative changes;
guilty;
stigam.
PTSD, post traumatic stress disorder; NET, narrative exposure therapy; WLC, waiting list control; NET-R, narrative exposure therapy revise; HADS, hospital anxiety and depression scale; MSPSS, the Multidimensional Scale of Perceived Social Supply; CiQQ-S, The Short Form of the Changes in Outlook Questionnaire; CAPS, the Clinician Administered PTSD Scale; MINI, Mini international Neuropsychiatrica; PSQ, the Perceived Stigmatization Questionnaire; TOP, termination of pregnancy; BDI, the Beck Depression Inventory; Zung, Zung Self Rating Depression Scale; NT, narrative therapy; HADS-D, hospital anxiety and depression scale-depression; PHQ-9, Patient Health Questionnaire; GAD-7, Generalized Anxiety Disorder-7; MFQ-C, Mentoring Functions Questionnaire; POMS-SF, Short form of the Profile of Mood States; SAS, Zung’s Self-Rating Anxiety Scale; SDS, Zung’s Self-Rating Depression Scale